-
LLC-PK1/MDR1 Model for BBB Permeability Prediction
2026-09-02
Hu et al. developed a high-throughput surrogate blood-brain barrier model by combining LLC-PK1-MOCK and LLC-PK1-MDR1 Transwell systems with a correction for lysosomal drug trapping. The study links in vitro permeability with unbound brain distribution and provides a practical framework for separating passive diffusion, P-glycoprotein efflux, and intracellular sequestration during early CNS drug screening.
-
AO/PI Staining Solution for Diabetic Nephropathy
2026-09-01
Translate diabetic nephropathy mechanism studies into cleaner viability measurements with dual fluorescent DNA dyes. AO/PI Staining Solution supports live dead cell discrimination, impurity exclusion, and reproducible fluorescence-based cell counting in podocyte and primary-cell workflows.
-
Lithium, Exosomal Wnt10a, and Bone Regeneration
2026-09-01
The 2024 ACS Applied Materials & Interfaces study identifies a mechanism by which lithium enhances osteogenesis: MARK2-dependent Rab11a/Rab11FIP1 trafficking increases exosomal Wnt10a secretion, activating β-catenin signaling in bone mesenchymal stem cells. Its comparison of lithium-conditioned exosomes and GelMA hydrogels provides a mechanistic and biomaterials framework for improving bone repair, while also highlighting the need for pathway-specific validation in future studies.
-
CTOP: A Causal Tool for μ-Opioid Circuit Research
2026-08-31
CTOP is a selective μ-opioid receptor antagonist for separating receptor-level causality from circuit-level observations. This guide connects CTOP pharmacology with recent findings on mechanical opioid hypersensitivity and provides a rigorous framework for binding, signaling, and pain mechanism research.
-
CTOP for μ-Opioid Receptor Signaling Studies
2026-08-31
CTOP provides a selective pharmacological way to test whether μ-opioid receptor activation drives cellular signaling, mechanical hypersensitivity, or opioid tolerance. This workflow connects receptor-level assays with the brain-to-spinal circuit identified in recent mouse pain research while emphasizing route controls, timing, and interpretation.
-
dhcr7 Knockout Grass Carp Shows GCRV Resistance
2026-08-30
A 2026 Aquaculture Reports study used CRISPR/Cas9 to disrupt dhcr7 in grass carp and found substantially improved survival after GCRV-II challenge, together with stronger antiviral responses and reduced tissue damage. The results provide in vivo evidence that cholesterol biosynthesis can influence antiviral defense and identify dhcr7 as a candidate target for disease-resistant aquaculture breeding.
-
Ampicillin Sodium: Mechanism and Research Benchmarks
2026-08-29
Ampicillin sodium is a β-lactam antibiotic used to study bacterial cell wall biosynthesis inhibition. Vendor-reported benchmarks include a transpeptidase IC50 of 1.8 μg/mL and an MIC of 3.1 μg/mL, but assay conditions should be confirmed before comparison across experiments.
-
DiscoveryProbe Stem Cell Compound Library Plus
2026-08-28
DiscoveryProbe Stem Cell Compound Library Plus supports mechanism-guided stem cell pathway profiling and high-content phenotypic screening. This article shows how quantitative cell-state readouts, pathway coverage, and orthogonal validation can convert a broad compound screen into defensible assay decisions.
-
Foretinib, ICD, and Anti-CD47 Therapy in Colorectal Cancer
2026-08-28
The reference study identifies foretinib as an inducer of immunogenic cell death in colorectal cancer, linking c-Met/VEGFR2 inhibition to p53–DR5 signaling, DAMP release, and immune activation. Its combination with anti-CD47 immunotherapy suggests a complementary strategy that couples tumor-cell killing with improved antitumor immune recognition.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody
2026-08-27
HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) provides an enzyme-labeled secondary reagent for detecting mouse IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be used as a default secondary for non-mouse or non-IgG primaries, fluorescent workflows, or assays that are incompatible with HRP substrates.
-
SU6656: Src Tyrosine Kinases Inhibitor Workflows
2026-08-27
SU6656 connects megakaryocyte polyploidization studies with endothelial radiosensitization workflows. This practical guide explains how to screen the compound in hiPSC-derived platelet production, compare it with alternative maturation modulators, and design controls for cancer research.
-
Luminescent ATP Detection Assay Kit for Colitis
2026-08-26
Use the Luminescent ATP Detection Assay Kit to add a quantitative bioenergetic layer to NOX2/ROS/mitochondrial studies of ulcerative colitis. Its acid-free lysis workflow supports cellular ATP quantification and ATP measurement in tissue samples while preserving material for protein-based follow-up.
-
Z-YVAD-FMK: Caspase-1 Inhibitor Workflows
2026-08-26
Z-YVAD-FMK provides a cell-permeable, irreversible way to test whether caspase-1 drives inflammatory signaling, pyroptosis, or secondary cell death. This guide turns the compound’s selectivity and solubility profile into practical cell-based, cancer research, and species-aware assay workflows.
-
Palonosetron hydrochloride Workflow Guide
2026-08-25
Build reproducible 5-HT3 receptor assays and connect nanomolar receptor pharmacology with OCT2 and MATE1 transporter studies. This workflow guide highlights concentration selection, translational model design, and practical troubleshooting for cancer research.
-
HLY78: Wnt/β-Catenin Pathway Modulator
2026-08-25
HLY78 is a ligand-dependent Wnt/β-catenin pathway modulator for connecting Axin–LRP6 signaling with developmental and fibrosis assays. This guide translates its mechanism into practical cell, zebrafish, and pathway-rescue workflows while separating established evidence from proposed applications.